Cargando…

Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines

Gemcitabine (GEM) and cisplatin (CDDP) combination therapy (GC) is the standard chemotherapy for advanced biliary tract cancer (BTC); however, its pharmacotherapeutic efficacy remains unclear. To investigate the effects of GC, we selected 11 from 17 BTC cell lines, according to their GEM sensitivity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sakamoto, Yasunari, Yamagishi, Seri, Okusaka, Takuji, Ojima, Hidenori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770112/ https://www.ncbi.nlm.nih.gov/pubmed/31484399 http://dx.doi.org/10.3390/cells8091026

Ejemplares similares

Establishment of various biliary tract carcinoma cell lines and xenograft models for appropriate preclinical studies
por: Ojima, Hidenori, et al.
Publicado: (2016)

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
por: Okusaka, T, et al.
Publicado: (2010)

Targeted Therapy for Biliary Tract Cancer
por: Furuse, Junji, et al.
Publicado: (2011)

A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer
por: Suzuki, Eiichiro, et al.
Publicado: (2013)

Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review
por: Fiteni, Frédéric, et al.
Publicado: (2014)

Comparison of the Efficacy between Gemcitabine-Cisplatin and Capecitabine-Cisplatin Combination Chemotherapy for Advanced Biliary Tract Cancer
por: Lee, Jieun, et al.
Publicado: (2015)

Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine
por: Ikeda, Masafumi, et al.
Publicado: (2017)

Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review
por: Park, Joon Oh, et al.
Publicado: (2015)

Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer
por: Inoue, Hiroto, et al.
Publicado: (2021)

Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer
por: Zeng, Tian-mei, et al.
Publicado: (2023)

Randomized phase III study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401‐ MITSUBA)
por: Ioka, Tatsuya, et al.
Publicado: (2022)

Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy
por: Suzuki, Yuko, et al.
Publicado: (2018)

Multidisciplinary Treatment of Patients with Progressive Biliary Tract Cancer after First-Line Gemcitabine and Cisplatin: A Single-Center Experience
por: Müller, Christian, et al.
Publicado: (2023)

A Cost-Effectiveness Analysis of Gemcitabine plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan
por: Tsukiyama, Ikuto, et al.
Publicado: (2016)

Stevens-Johnson Syndrome Patient Received Combination Chemotherapy Gemcitabine, Cisplatin, and 5-FU for Biliary Tract Cancer
por: Aznab, Mozaffar, et al.
Publicado: (2016)

Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin
por: Hyung, Jaewon, et al.
Publicado: (2019)

Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine—A Randomized Phase II Trial
por: Markussen, Alice, et al.
Publicado: (2020)

Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study
por: Lee, Sang Hoon, et al.
Publicado: (2020)

Germline mutations in cancer-predisposition genes in patients with biliary tract cancer
por: Terashima, Takeshi, et al.
Publicado: (2019)

Phase I study of neoadjuvant S‐1 plus cisplatin with concurrent radiation for biliary tract cancer (Tokyo Study Group for Biliary Cancer: TOSBIC02)
por: Abe, Yuta, et al.
Publicado: (2023)

Antireflux Metal Stent for Initial Treatment of Malignant Distal Biliary Obstruction
por: Morita, Shinichi, et al.
Publicado: (2018)

Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113
por: Ueno, Makoto, et al.
Publicado: (2021)

Effect of midkine on gemcitabine resistance in biliary tract cancer
por: Lu, Yongliang, et al.
Publicado: (2018)

Pharmacotherapeutic and Non-Pharmacological Options for Refractory and Difficult-to-Treat Seizures
por: Mitchell, James W., et al.
Publicado: (2012)

RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin
por: Chun, Jung Won, et al.
Publicado: (2021)

A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study
por: Bridgewater, John, et al.
Publicado: (2016)

A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin
por: Zheng, Yi, et al.
Publicado: (2018)

Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer
por: Harder, J, et al.
Publicado: (2006)

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
por: Valle, Juan W, et al.
Publicado: (2015)

Erratum to: A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study
por: Bridgewater, John, et al.
Publicado: (2016)

Histological complete response in a patient with advanced biliary tract cancer treated by gemcitabine/cisplatin/S-1 combination chemotherapy: A case report
por: Matsubara, Tokuhiro, et al.
Publicado: (2016)

Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study
por: Siebenhüner, Alexander R., et al.
Publicado: (2018)

Clinical outcomes of second‑line chemotherapy after gemcitabine and cisplatin plus S‑1 treatment for patients with advanced biliary tract cancer in the KHBO1401‑3A study
por: Shindo, Yoshitaro, et al.
Publicado: (2023)

Anticancer properties of cannabidiol and Δ(9)-tetrahydrocannabinol and synergistic effects with gemcitabine and cisplatin in bladder cancer cell lines
por: Whynot, Erin G., et al.
Publicado: (2023)

Clinical characteristics of pancreatic and biliary tract cancers associated with Lynch syndrome
por: Takamizawa, Shigemasa, et al.
Publicado: (2021)

Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin
por: Jeong, Hyehyun, et al.
Publicado: (2021)

Feasibility and efficacy evaluation of metallic biliary stents eluting gemcitabine and cisplatin for extrahepatic cholangiocarcinoma
por: Xiao, Jing-Bo, et al.
Publicado: (2020)

Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients
por: Kim, Bum Jun, et al.
Publicado: (2017)

Prognostic and predictive factors for Taiwanese patients with advanced biliary tract cancer undergoing frontline chemotherapy with gemcitabine and cisplatin: a real-world experience
por: Wu, Chiao-En, et al.
Publicado: (2020)

Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis
por: Cheon, Jaekyung, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d2b7gunl1fgntl157beheblduf